ReviewMedecine tropicale et sante internationale2024
[Hepatocellular carcinoma (HCC)].
Review in Medecine tropicale et sante internationale, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- ADAM19: biological characteristics and implications in disease pathology and clinical applications.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Efficacy of targeted hepatocellular carcinoma therapy using modified response evaluation criteria in solid tumors and alpha-fetoprotein: A single center retrospective exploratory study.Annals of hepato-biliary-pancreatic surgery · 2026Article
- Hepatotoxicity of immune checkpoint inhibitor plus targeted therapy versus tyrosine kinase inhibitor monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.Translational cancer research · 2026Article
- Advances in oncolytic viruses immunotherapy of hepatocellular carcinoma.Discover oncology · 2026Review
- PTTG3P-miR-142-5p-IGF2BP3 axis governs ferroptosis in hepatocellular carcinoma.Discover oncology · 2026Article
- Signalling pathways in hepatocellular carcinoma (HCC) metastasis and invasion: Molecular mechanisms and therapeutic implications.Biochemistry and biophysics reports · 2026Review
- Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma with obstructive jaundice: A case report and review of literature.World journal of gastrointestinal oncology · 2026Article
- CECT Radiomics and Liver Fibrosis Markers for Predicting Early Recurrence in Older Patients with Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- A Prognostic 9-Gene Signature Linked to Autophagy-Dependent Cell Death in Hepatocellular Carcinoma.Cancer informatics · 2026Article
- EXOSC3 knockdown induces G1/S phase arrest to suppress hepatocellular carcinoma cell proliferation.Scientific reports · 2025Article
- Therapeutic efficacy of WSiScience · 2025Article
- Diagnostic performance of serum origin recognition complex subunit 1 protein for hepatitis B virus-related hepatocellular carcinoma.World journal of gastroenterology · 2025Article
- The effect of interval time of transcatheter arterial chemoembolization with drug-eluting beads on the efficacy and safety of unresectable hepatocellular carcinoma: a case-control study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary liver cancers are tumors that develop from different liver cells. Hepatocellular carcinoma (HCC), which develops from hepatocytes, accounts for approximately 75-85% of primary liver cancers.HCC is the 6
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.